ClinicalTrials.gg

Program

Valsartan

Also written as “valsartan”, “sacubitril/valsartan” and “valsartan plus hydrochlorothiazide”.

Its studies are mostly in Hypertension · Essential Hypertension · Heart Failure · Diabetes Mellitus, Type 2 · Proteinuria, led by 14 companies.

Furthest: phase 4, since Sep 10, 2005125 company-led studies, 1 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis1060 open or runningphase 4since Sep 10, 2005Nov 30, 2004none ahead
LG Chem50 open or runningphase 3since Aug 5, 2013May 11, 2010none ahead
IlDong Pharmaceutical20 open or runningphase 3since May 20, 2014May 20, 2014none ahead
Sun Pharmaceutical Industries20 open or runningno phasesince Jul 21, 2014Jul 21, 2014none ahead
ARKAY Therapeutics10 open or runningphase 2since Sep 23, 2018Sep 23, 2018none ahead
Dexa Medica Group10 open or runningno phasesince Aug 3, 2015Aug 3, 2015none ahead
EMS10 open or runningphase 3since Nov 23, 2015Nov 23, 2015none ahead
farma-de-colombia-sa10 open or runningphase 3since May 7, 2013May 7, 2013none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Jul 30, 2015Jul 30, 2015none ahead
Hanlim Pharm.10 open or runningphase 1since Aug 2, 2018Aug 2, 2018none ahead
JW Pharmaceutical10 open or runningphase 1since Jul 26, 2011Jul 26, 2011none ahead
Lunan Pharmaceutical Group11 open or runningphase 3since Mar 4, 2025Mar 4, 2025Dec 2027phase 3 · NCT06863987
tsh-biopharm-corporation-limited10 open or runningphase 4since Feb 4, 2014Feb 4, 2014none ahead
Yuhan10 open or runningphase 1since Jan 5, 2012Jan 5, 2012none ahead

Also a collaborator on its studies: Bristol-Myers Squibb, GlaxoSmithKline and Bayer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Jan 22, 2007.

  1. Jan 15, 2015Phase 1 study in HypertensionIlDong Pharmaceutical · NCT02343250 · 54 enrolled
  2. Jul 30, 2015Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT02519010 · 36 enrolled · Egypt
  3. Aug 3, 2015Dexa Medica Group's first study: no phase study in HealthyNew to Dexa Medica GroupDexa Medica Group · NCT02518451 · 48 enrolled · Indonesia
  4. Nov 23, 2015EMS's first study: phase 3 study in HypertensionNew to EMSEMS · NCT02662894
  5. Feb 23, 2017Phase 3 study in Cardiovascular DiseasesNovartis · NCT03066804 · 2,572 enrolled · United States, Argentina, Austria and more
  6. May 8, 2018Phase 1 study in Healthy Male VolunteersLG Chem · NCT03532854 · 42 enrolled · Korea, Republic of
  7. Aug 2, 2018Hanlim Pharm.'s first study: phase 1 study in HypertensionNew to Hanlim Pharm.Hanlim Pharm. · NCT03648333 · 27 enrolled
  8. Sep 23, 2018ARKAY Therapeutics's first study: phase 2 study in Diabetes Mellitus, Type 2New to ARKAY TherapeuticsARKAY Therapeutics · NCT03686657 · United States
  9. Dec 20, 2018Phase 3 study in Heart FailureNovartis · NCT03785405 · 216 enrolled · United States, Argentina, Austria and more
  10. Jun 13, 2019Phase 3 study in Heart Failure With Preserved Ejection Fraction (HFpEF)Novartis · NCT03988634 · 467 enrolled · United States, Canada
  11. Jul 10, 2019Phase 4 study in Chagas DiseaseNovartis · NCT04023227 · 922 enrolled · Argentina, Brazil, Colombia and more
  12. Nov 4, 2020Phase 3 study in Post Myocardial InfarctionNovartis · NCT04637555
  13. Nov 13, 2023Phase 3 study in Heart FailureNovartis · NCT06149104 · 8 enrolled · Japan
  14. Mar 4, 2025Lunan Pharmaceutical Group's first study: phase 3 study in Essential HypertensionNew to Lunan Pharmaceutical GroupLunan Pharmaceutical Group · NCT06863987 · 342 planned · China

Ahead

  1. Dec 2027Primary completion: phase 3 study in Essential HypertensionLunan Pharmaceutical Group · NCT06863987

TargetBeta

AGTR1 →read by rule
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule

Other programs on AGTR1

ProgramCompanyFurthest phaseStudies
TelmisartanruleBoehringer Ingelheimphase 4132
LosartanruleOrganonphase 458
azilsartan medoxomilruleTakedaphase 425
sparsentanruletravere-therapeutics-incphase 49

Studies

The newest 60 of 125 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06863987Essential Hypertension · China3By invitationLunan Pharmaceutical GroupDec 2027342
NCT06149104Heart Failure · Japan3CompletedNovartisAug 14, 20248
NCT04637555Post Myocardial Infarction3WithdrawnNovartisJun 1, 20230
NCT04023227Chagas Disease · Argentina, Brazil, Colombia and more4CompletedNovartisMar 16, 2025922
NCT03988634Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Canada3CompletedNovartisDec 14, 2022467
NCT03785405Heart Failure · United States, Argentina, Austria and more3CompletedNovartisDec 29, 2023216
NCT03686657Diabetes Mellitus, Type 2 · United States2WithdrawnARKAY TherapeuticsDec 26, 20300
NCT03648333Hypertension1CompletedHanlim Pharm.Feb 201427
NCT03532854Healthy Male Volunteers · Korea, Republic of1CompletedLG ChemAug 25, 201842
NCT03066804Cardiovascular Diseases · United States, Argentina, Austria and more3CompletedNovartisOct 28, 20192,572
NCT02662894Hypertension3WithdrawnEMSSep 20200
NCT02518451Healthy · Indonesia–CompletedDexa Medica GroupOct 201348
NCT02519010Healthy · Egypt1CompletedGenuine Research Center, EgyptMar 201136
NCT02343250Hypertension1CompletedIlDong PharmaceuticalMar 201554
NCT02197494Healthy · India–CompletedSun Pharmaceutical IndustriesFeb 201440
NCT02197442Healthy · India–CompletedSun Pharmaceutical IndustriesFeb 201436
NCT02145104Hypertension · Korea, Republic of3CompletedIlDong PharmaceuticalJun 7, 2016286
NCT02062645Essential Hypertension · Turkey4CompletedNovartisSep 2015115
NCT02058446Essential Hypertension · Taiwan4Completedtsh-biopharm-corporation-limitedMar 201436
NCT01928628Hypertension · Korea, Republic of3CompletedLG ChemApr 2013449
NCT01918358Hypertension · Korea, Republic of1CompletedLG ChemJan 201360
NCT01918332Hypertension · Korea, Republic of3CompletedLG ChemMar 2013168
NCT01850160Hypertension · Colombia, Ecuador3Completedfarma-de-colombia-saMar 2015124
NCT01617681Hypertension · Belgium, Brazil, France and more3CompletedNovartisJan 24, 2017127
NCT01541189Hypertension · China4CompletedNovartisJan 2013200
NCT01609907Hypertension · Korea, Republic of1CompletedYuhanMay 201230
NCT01447485Hypertension · Japan1CompletedNovartisOct 201112
NCT01406431Hyperlipidemias · Korea, Republic of1CompletedJW PharmaceuticalAug 201148
NCT01365481Hypertension · Colombia, Finland, Germany and more3CompletedNovartisSep 2015150
NCT01281306Isolated Systolic Hypertension · United States, Argentina, Canada and more2CompletedNovartisDec 2011910
NCT01241487Essential Hypertension · Egypt4CompletedNovartisJan 2011150
NCT01167153Hypertension · China4CompletedNovartisApr 2011564
NCT01122251Essential Hypertension · Korea, Republic of2CompletedLG ChemMay 2010441
NCT01001572Essential Hypertension3CompletedNovartisMay 2010932
NCT00939588Hypertension · Russian Federation2CompletedNovartisDec 200988
NCT00931710Isolated Systolic Hypertension · United States4CompletedNovartisJan 2010488
NCT00902304Hypertension · United States, Australia4CompletedNovartisJul 20112,337
NCT00821574Hypertension4CompletedNovartisMar 2007144
NCT00809926Hypertension · United States4CompletedNovartisJul 2009451
NCT00698646Hypertension · United States4CompletedNovartisJun 2009384
NCT00699192Hypertension · Czech Republic, Finland, France and more3CompletedNovartisMay 2009965
NCT00666536Hypertension · United States4CompletedNovartisJan 2009728
NCT00687973Hypertension · France4CompletedNovartisJan 2009393
NCT00700271Hypertension · France, Tunisia4CompletedNovartisAug 2008478
NCT00550095Proteinuria · Egypt4CompletedNovartisNov 2009509
NCT00548067Hypertension · India3CompletedNovartis111
NCT00523744Hypertension · Germany3CompletedNovartisDec 2007257
NCT00523549Hypertension · United States4CompletedNovartisJan 2008229
NCT00487123Hypertension · Singapore4CompletedNovartisSep 2007
NCT00457626Hypertension · United States, Belgium, Brazil and more3CompletedNovartisMay 25, 200966
NCT00446563Hypertension · Germany3CompletedNovartisMar 201090
NCT00446524Hypertension · Japan3CompletedNovartisOct 2008403
NCT00446511Hypertension · United States, Belgium, France and more3CompletedNovartisJun 2009250
NCT00439738Hypertension · United States4CompletedNovartisNov 2007412
NCT00437645Essential Hypertension · Argentina, Chile, Ecuador and more3CompletedNovartisNov 20071,183
NCT00435162Hypertension · United States, Belgium, Brazil and more3CompletedNovartisJan 200974
NCT00433836Hypertension · United States, Belgium, France and more3CompletedNovartisFeb 2009300
NCT00426478Hypertension · Taiwan4CompletedNovartis80
NCT00425997Hypertension · United States4CompletedNovartisOct 2007480
NCT00425373Essential Hypertension · Japan3CompletedNovartisMar 20081,474

How it is read

Names in the registry

  • “Valsartan”, 31 entries
  • “valsartan”, 23 entries
  • “sacubitril/valsartan”, 5 entries
  • “valsartan plus hydrochlorothiazide”, 5 entries
  • “valsartan + amlodipine”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.